Pathologies | Etude - Nom | Etude -code | Titre | Eudract | NCT | Phase | PI |
Poumons et Thorax | ANAM-17-21 | ANAM-17-21 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated
weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC) | 2018-002927-40 | NCT03743064 | Phase 3 | Colinet Benoît |
Poumons et Thorax | CA001-050 | CA001-050 | A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | | NCT04702880 | Phase 2 | Colinet Benoît |
Poumons et Thorax | CodeBreaK 100 | 20170543 | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100) | 2018-001400-11 | NCT03600883 | Phase 2 | Colinet Benoît |
Poumons et Thorax | EXCLAIM-2 | TAK-788-3001 | Phase III clinical trial evaluating TAK-788 versus platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) as first-line treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
| 2019-001845-42 | NCT04129502 | Phase 3 | Colinet Benoît |
Poumons et Thorax | MARIPOSA | 73841937NSC3003 (Labcorp Project #: 210418) | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer – MARIPOSA | 2020-000743-31 | NCT04487080 | Phase 3 | Colinet Benoît |
Poumons et Thorax | MK7684A-002 | MK7684A-002 | A Phase 2, Multi-center, Randomized Study to Compare the Efficacy and Safety of MK-7684A Or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With A Platinum Doublet Chemotherapy and Immunotherapy | 2020-004034-38 | NCT04725188 | Phase 2 | Colinet Benoît |
Poumons et Thorax | PACIFIC-4 | D9103C00001 | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | 2018-002572-41 | NCT03833154 | Phase 3 | Colinet Benoît |
Poumons et Thorax | PDC-Lung-101 | PDC-Lung-101 | An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) | 2018-002382-19 | NCT03970746 | Phase 1a | Colinet Benoît |
Poumons et Thorax | SAPPHIRE | 516-005 | A randomized phase 3 study of Sitravatinib in combination with Nivolumab versus Docetaxel in patients with advanced non-squamous non-small cell lung cancer with disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy. | 2019-001043-41 | NCT03906071 | Phase 3 | Canon Jean-Luc |
Poumons et Thorax | Skyscraper 03 | GO41854 | A phase 3, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage 3 non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation. | 2019-0044773-29 | NCT04513925 | Phase 3 | Colinet Benoît |
Toutes Tumeurs | DF1001-001 | DF1001-001 | A phase I/II, first-in-human, multi-part, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expansion in selected indications | 2019-004706-10 | NCT04143711 | Phase 2 | Canon Jean-Luc |
Toutes Tumeurs | BALLETT | BSMO2020-2 | A study to examine the clinical value of comprehensive genomic profiling performed by Belgian NGS laboratories: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre - Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) | | NCT05058937 | Prospective-Collection d'échantillons | Canon Jean-Luc |
Toutes Tumeurs | Precision 1 | BSMO 2014-2 | The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment
“PRECISION 1”
| | NCT03873103 | Prospective-Collection d'échantillons | Canon Jean-Luc |
Toutes Tumeurs | Precision 2 - Afatinib | 1200.264 | Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation followed by the addition of paclitaxel to afatinib at disease progression. | 2016-003411-34 | NCT03810872 | Phase 2 | Canon Jean-Luc |
Toutes Tumeurs | Precision 2 – Olaparib | 1-2018 BSMO | Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. SAUF SEIN, OVAIRE, PROSTATE, ATM gene
| 2018-002966-37 | NCT03967938 | Phase 2 | Canon Jean-Luc |
Toutes Tumeurs | SGNTUC-019 | SGNTUC-019 | A phase 2 basket study of Tucatinib in combination with Trastuzumab in subjects with previously treated, locally advanced unresectable or metastatic solid tumors driven by HER2 alterations | | NCT04579380 | Phase 2 | Canon Jean-Luc |
Toutes Tumeurs | TAPISTRY | BO41932 | Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in patients with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by an next-generation-sequencing (NGS) assay | 2020-001847-16 | NCT04589845 | Phase 2 | Canon Jean-Luc |